PlexCOVID-19

About Plexision

Plexision is a privately held diagnostics company focused on personalizing care in transplantation and immunology through proprietary cellular biomarker tests. Its core technology measures antigen-specific white blood cells to predict risks such as organ rejection or viral reactivation. The company has achieved commercial traction with its FDA-approved Pleximmune test for pediatric liver/intestinal transplant rejection and a suite of lab-developed tests (LDTs) offered from its CLIA lab. Plexision also engages in custom biomarker R&D services for pharmaceutical partners, positioning itself at the intersection of diagnostics and drug development.

Therapeutic Areas